Nawal Bendris

969 total citations
16 papers, 686 citations indexed

About

Nawal Bendris is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Nawal Bendris has authored 16 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 11 papers in Cell Biology. Recurrent topics in Nawal Bendris's work include Cancer-related Molecular Pathways (7 papers), Microtubule and mitosis dynamics (5 papers) and Cellular transport and secretion (4 papers). Nawal Bendris is often cited by papers focused on Cancer-related Molecular Pathways (7 papers), Microtubule and mitosis dynamics (5 papers) and Cellular transport and secretion (4 papers). Nawal Bendris collaborates with scholars based in United States, France and Spain. Nawal Bendris's co-authors include Bénédicte Lemmers, Jean Marie Blanchard, Sandra L. Schmid, Nikola Arsic, Carlos R. Reis, Ping‐Hung Chen, Jean‐Marie Blanchard, Marion Peter, Cosette Rebouissou and Christina Begon‐Pescia and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Nawal Bendris

15 papers receiving 679 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nawal Bendris United States	13	477	212	181	118	74	16	686
Georgina P. Coló Argentina	16	406 0.9×	213 1.0×	189 1.0×	120 1.0×	72 1.0×	24	761
María José Sandí France	13	462 1.0×	166 0.8×	183 1.0×	127 1.1×	74 1.0×	21	738
Trine Bøttzauw Denmark	6	683 1.4×	166 0.8×	281 1.6×	140 1.2×	75 1.0×	6	978
Liliana Krasińska France	12	561 1.2×	235 1.1×	234 1.3×	135 1.1×	96 1.3×	18	910
Geun‐Hyoung Ha South Korea	18	631 1.3×	201 0.9×	268 1.5×	187 1.6×	89 1.2×	32	899
Frankie Chi Fat Ko Hong Kong	17	544 1.1×	241 1.1×	130 0.7×	192 1.6×	48 0.6×	29	775
Maider Ibarrola‐Villava Spain	16	310 0.6×	185 0.9×	214 1.2×	136 1.2×	52 0.7×	31	658
Margret B. Einarson United States	16	524 1.1×	161 0.8×	163 0.9×	118 1.0×	78 1.1×	28	760
Guo-Lei Zhou United States	12	447 0.9×	203 1.0×	119 0.7×	89 0.8×	51 0.7×	21	696
Ju He United States	14	606 1.3×	206 1.0×	238 1.3×	97 0.8×	58 0.8×	21	880

Countries citing papers authored by Nawal Bendris

Since Specialization

Citations

This map shows the geographic impact of Nawal Bendris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nawal Bendris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nawal Bendris more than expected).

Fields of papers citing papers by Nawal Bendris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nawal Bendris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nawal Bendris. The network helps show where Nawal Bendris may publish in the future.

Co-authorship network of co-authors of Nawal Bendris

This figure shows the co-authorship network connecting the top 25 collaborators of Nawal Bendris. A scholar is included among the top collaborators of Nawal Bendris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nawal Bendris. Nawal Bendris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Hanna, Glenn J., Douglas R. Adkins, Jacob Thomas, et al.. (2024). FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). TPS4607–TPS4607.

Witzig, Thomas E., Lubomir Sokol, Alejandro Martı́n, et al.. (2024). Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood Advances. 8(17). 4581–4592. 7 indexed citations

Witzig, Thomas E., Lubomir Sokol, Won Seog Kim, et al.. (2021). Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood. 138(Supplement 1). 621–621. 6 indexed citations

Chen, Ping‐Hung, Nawal Bendris, Yi‐Jing Hsiao, et al.. (2017). Crosstalk between CLCb/Dyn1-Mediated Adaptive Clathrin-Mediated Endocytosis and Epidermal Growth Factor Receptor Signaling Increases Metastasis. Developmental Cell. 40(3). 278–288.e5. 63 indexed citations

Reis, Carlos R., Ping‐Hung Chen, Nawal Bendris, & Sandra L. Schmid. (2017). TRAIL-death receptor endocytosis and apoptosis are selectively regulated by dynamin-1 activation. Proceedings of the National Academy of Sciences. 114(3). 504–509. 56 indexed citations

Bendris, Nawal & Sandra L. Schmid. (2016). Endocytosis, Metastasis and Beyond: Multiple Facets of SNX9. Trends in Cell Biology. 27(3). 189–200. 55 indexed citations

Bendris, Nawal, et al.. (2016). Sorting nexin 9 negatively regulates invadopodia formation and function in cancer cells. Journal of Cell Science. 129(14). 2804–2816. 20 indexed citations

Bendris, Nawal, Karla C. Williams, Carlos R. Reis, et al.. (2016). SNX9 promotes metastasis by enhancing cancer cell invasion via differential regulation of RhoGTPases. Molecular Biology of the Cell. 27(9). 1409–1419. 38 indexed citations

Bendris, Nawal, Carlos R. Reis, Yunyun Zhou, et al.. (2015). A Systematic Analysis Reveals Heterogeneous Changes in the Endocytic Activities of Cancer Cells. Cancer Research. 75(21). 4640–4650. 39 indexed citations

10.

Cheung, Caroline, Nawal Bendris, Conception Paul, et al.. (2015). Cyclin A2 modulates EMT via β-catenin and phospholipase C pathways. Carcinogenesis. 36(8). 914–924. 25 indexed citations

11.

Bendris, Nawal, Bénédicte Lemmers, & Jean Marie Blanchard. (2015). Cell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors. Cell Cycle. 14(12). 1786–1798. 123 indexed citations

12.

Bendris, Nawal, Caroline Cheung, Hon S. Leong, et al.. (2014). Cyclin A2, a novel regulator of EMT. Cellular and Molecular Life Sciences. 71(24). 4881–4894. 22 indexed citations

13.

Bendris, Nawal, Caroline Cheung, Nikola Arsic, et al.. (2012). Cyclin A2: a genuine cell cycle regulator?. BioMolecular Concepts. 3(6). 535–543. 23 indexed citations

14.

Bendris, Nawal, Nikola Arsic, Bénédicte Lemmers, & Jean Marie Blanchard. (2012). Cyclin A2, Rho GTPases and EMT. Small GTPases. 3(4). 225–228. 53 indexed citations

15.

Arsic, Nikola, Nawal Bendris, Marion Peter, et al.. (2012). A novel function for Cyclin A2: Control of cell invasion via RhoA signaling. The Journal of Cell Biology. 196(1). 147–162. 102 indexed citations

16.

Bendris, Nawal, Bénédicte Lemmers, Jean‐Marie Blanchard, & Nikola Arsic. (2011). Cyclin A2 Mutagenesis Analysis: A New Insight into CDK Activation and Cellular Localization Requirements. PLoS ONE. 6(7). e22879–e22879. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact